Active Ingredient: Sumatriptan
Sumatriptan is indicated for the acute relief of migraine attacks, with or without aura. Sumatriptan should only be used where there is a clear diagnosis of migraine.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, between 50 milligrams sumatriptan and 100 milligrams sumatriptan, 1 to 2 times daily. The maximum allowed total dose is 300 milligrams sumatriptan daily.
It is advisable that sumatriptan be given as early as possible after the onset of migraine attack but it is equally effective at whatever stage of the attack it is administered.
The recommended dose is 50 mg. Some patients may require 100 mg.
If the patient has responded to the first dose but the symptoms recur a second dose may be given provided that there is a minimum interval of two hours between the two doses. No more than 300 mg should be taken in any 24 hour period.
Patients who do not respond to the prescribed dose of sumatriptan should not take a second dose for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. Imigran may be taken for subsequent attacks.
Sumatriptan is recommended as monotherapy for the acute treatment of migraine and should not be given concomitantly with ergotamine or derivatives of ergotamine (including methysergide).
For:
Nasal, between 10 milligrams sumatriptan and 20 milligrams sumatriptan, 1 to 2 times daily. The maximum allowed total dose is 40 milligrams sumatriptan daily.
It is advisable that sumatriptan be given as early as possible after the onset of a migraine headache. It is equally effective at whatever stage of the attack it is administered.
The optimal dose of sumatriptan nasal spray is 20 mg for administration into one nostril. However, due to inter/intra patient variability of both the migraine attacks and the absorption of sumatriptan, 10 mg may be effective in some patients.
If a patient does not respond to the first dose of sumatriptan, a second dose should not be taken for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid or non-steroidal anti-inflammatory drugs. Sumatriptan may be taken for subsequent attacks.
If the patient has responded to the first dose but the symptoms recur, a second dose may be given in the following 24 hours, provided that there is a minimum interval of 2 hours between the two doses.
No more than two doses of sumatriptan 20 mg nasal spray should be taken in any 24-hour period.
For:
Subcutaneous, 6 milligrams sumatriptan, 1 to 2 times daily. The maximum allowed total dose is 12 milligrams sumatriptan daily.
It is recommended to start the treatment at the first sign of a migraine headache or associated symptoms such as nausea, vomiting or photophobia. It is equally effective at whatever stage of the attack it is administered.
The efficacy of sumatriptan is independent of the duration of the attack when starting treatment. Administration during a migraine aura prior to other symptoms occurring may not prevent the development of a headache.
The recommended adult dose of sumatriptan is a single 6 mg subcutaneous injection.
If a patient does not respond to the first dose of sumatriptan, a second dose should not be taken for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. Sumatriptan injection may be taken for subsequent attacks.
If the patient has responded to the first dose, but the symptoms recur a second dose may be given in the next 24 hours, provided that there is a minimum interval of 1 hour between the two doses.
The maximum dose in 24 hours is two 6 mg injections (12 mg).
For:
Rectal, 25 milligrams sumatriptan, 1 to 2 times daily. The maximum allowed total dose is 50 milligrams sumatriptan daily.
For:
Nasal, 10 milligrams sumatriptan, 1 to 2 times daily. The maximum allowed total dose is 20 milligrams sumatriptan daily.
It is advisable that sumatriptan be given as early as possible after the onset of a migraine headache. It is equally effective at whatever stage of the attack it is administered.
Use of sumatriptan in adolescents should be on the recommendation of a specialist or physician who has significant experience in treating migraine, taking into account local guidance.
The recommended dose of sumatriptan nasal spray is 10 mg for administration into one nostril.
If a patient does not respond to the first dose of sumatriptan, a second dose should not be taken for the same attack. In these cases the attack can be treated with paracetamol, acetylsalicylic acid or non-steroidal anti-inflammatory drugs. Sumatriptan may be taken for subsequent attacks.
If the patient has responded to the first dose but the symptoms recur, a second dose may be given in the following 24 hours, provided that there is a minimum interval of 2 hours between the two doses.
No more than two doses of sumatriptan 10 mg nasal spray should be taken in any 24-hour period.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
